左旋多巴
苄丝肼
卡比多巴
医学
帕金森病
麻醉
药理学
内科学
疾病
作者
William C. Koller,Rajesh Pahwa
出处
期刊:PubMed
日期:1994-07-01
卷期号:44 (7 Suppl 6): S23-8
被引量:15
摘要
A major problem in the long-term treatment of Parkinson's disease with chronic, intermittent levodopa therapy is fluctuations in motor response. Both peripheral and central pharmacokinetic properties of levodopa are important in determining the duration of response. The "wearing-off" phenomenon or "end-of-dose" deterioration is related directly to the level of plasma levodopa. Therefore, a principal strategy for the treatment of motor fluctuations has been the attempt to prolong levodopa plasma levels with the use of long-acting, controlled-release levodopa preparations. This paper reviews the available data on the two compounds that are commercially available: benserazide-levodopa hydrodynamically balanced system (Madopar HBS) and controlled-release carbidopa-levodopa (Sinemet CR).
科研通智能强力驱动
Strongly Powered by AbleSci AI